Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9–20

Article  PubMed  PubMed Central  CAS  Google Scholar 

Weger VA, Schtte T, Konings IRHM et al (2023) Successful trastuzumab-deruxtecan rechallenge after interstitial lung disease: a case report. J Breast Cancer 26(5):519–523

Article  PubMed  PubMed Central  Google Scholar 

Tarantino P, Mode S, Tolaney SM et al (2021) Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol 7:1873–1881

Article  PubMed  Google Scholar 

Kumagai K, Aida T, Tsuchiya Y et al (2020) Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci 111:4636–4645

Article  PubMed  PubMed Central  CAS  Google Scholar 

Curigliano G, Mueller V, Borges V et al (2022) Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 33(3):321–329

Article  PubMed  CAS  Google Scholar 

Stanowicka-grada M, Senkus E (2023) Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Curr Treat Options Onco 24(11):1633–1650

Article  Google Scholar 

Swain SM, Nishino M, Lancaster L et al (2022) Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease / pneumonitis -Focus on proactive monitoring, diagnosis, and management. Caner Treat Rev 106:102378

Article  CAS  Google Scholar 

Abuhelwa Z, Alloghbi A, Algahtani A et al (2022) Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: A systematic review. Drugs 82(9):979–987

Article  PubMed  PubMed Central  CAS  Google Scholar 

Saura C, Modi S, Krop I et al (2024) Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 35(3):302–307

Article  PubMed  CAS  Google Scholar 

Hurvitz SA, Hegg R, Chung WP et al (2023) Trastuzumab deruxtecan versus Trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY breast03, a randomized, open-label, phase 3 trial. Lancet Oncol 401:105–117

Article  CAS  Google Scholar 

Shitara K, Bang YJ, Iwasa S et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 283(25):2419–2430

Article  Google Scholar 

Custem EV, Bartolomeo M, Smyth E et al (2023) Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol 24(7):744–756

Article  Google Scholar 

Li BT, Smit EF, Goto Y et al (2022) Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 286(3):241–251

Article  Google Scholar 

Goto K, Goto Y, Kubo T et al (2023) Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomaized, phase II DESTINY-Lung02 trail. J Clin Oncol 41(31):4852–4863

Article  PubMed  PubMed Central  CAS  Google Scholar 

Meric-Bernstam MV, Oaknin A et al (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42(1):47–58

Article  PubMed  CAS  Google Scholar 

Hackchaw MD, Danysh HE, Singh J et al (2020) Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat 183(1):23–39

Article  Google Scholar 

US Food and Drug Administration. Highlights of prescribing information 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf. Accessed 8 Aug 2024

Kubo K, Azuma A, Kanazawa M et al (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Invest 51(4):260–277

Article  Google Scholar 

Rugo GS, Bianchini G, Cortes J et al (2022) Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 7(4):100553

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cortes J, Kim SB, Chung WP et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143–1154

Article  PubMed  CAS  Google Scholar 

Ogata T, Fujita Y, Muro K (2022) Dramatic response to trastuzumab deruxtecan rechallenge in a patient with HER2-positive gastric cancer: a case report. Am J Case Rep. https://doi.org/10.12659/AJCR935600

Article  PubMed  Google Scholar 

Moss NS, Tosi U, Santomasso BD et al (2022) Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. CNS Oncol. https://doi.org/10.2217/cns-2022-0010

Article  PubMed  Google Scholar